Omeros Earnings: Here’s Why Shares are Down Now

Omeros Corporation (NASDAQ:OMER) had a loss and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are down 0.19%.

Omeros Corporation Earnings Cheat Sheet

Results: Adjusted Earnings Per Share increased to $-0.3 in the quarter versus EPS of $-0.46 in the year-earlier quarter.

Revenue: Rose 38.6% to $1.58 million from the year-earlier quarter.

Actual vs. Wall St. Expectations: Omeros Corporation reported adjusted EPS loss of $0.3 per share. By that measure, the company beat the mean analyst estimate of $-0.34. It beat the average revenue estimate of $1.5 million.

Quoting Management: The PDUFA “has provided critical resources for improving the quality and timeliness of premarket review of drugs,” said FDA spokeswoman, Sandy Walsh. “These accomplishments could not have been achieved without the innovations of the biopharmaceutical industry and the dedication and skill of FDA’s drug review staff.”

Key Stats (on next page)…